Merck KGaA in talks to sell its biosimilars R&D ops as shakeout looms
The biosimilars business is just getting established, but the shakeout among a group of high-powered rivals is already taking shape.
Merck KGaA CEO Stefan Oschmann told reporters this morning that the company is deep in talks to sell its biosimilars group, according to Reuters, dickering on a unit that has been targeting some familiar blockbusters like Humira (AbbVie), Rituxan (Roche) and Neulasta (Amgen).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.